Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
N4 Pharma ( (GB:N4P) ) has shared an update.
N4 Pharma has announced significant progress in its collaboration with the University of Strathclyde, focusing on the development of its Nuvec® gene delivery system. The company is working towards key studies in 2026 to demonstrate Nuvec®’s benefits over lipid nanoparticles, particularly in stability and targeting capabilities. Recent achievements include successful preclinical demonstrations in inflammatory bowel disease and non-small cell lung cancer, positioning Nuvec® as a competitive alternative in RNA therapeutic delivery. The company has also strengthened its intellectual property portfolio with new patent filings, enhancing its market position and potential for future partnerships.
More about N4 Pharma
N4 Pharma plc is a UK-based biotechnology company focused on developing Nuvec®, a proprietary gene delivery system designed to enable advanced therapies for cancer and other diseases. The company is involved in the development of RNA-based therapeutics, with a particular emphasis on improving delivery mechanisms compared to current industry standards.
Average Trading Volume: 2,578,849
Technical Sentiment Signal: Sell
Current Market Cap: £4.37M
For an in-depth examination of N4P stock, go to TipRanks’ Overview page.